Suven discovery research is focused on discovering and developing new chemical entities (NCEs), which are best in class central nervous system therapies for the treatment of cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastro-intestinal motility disorders. Research targets includes serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal (Dopaminergic and seretonergic receptor) and P2X purinoceptor 7 receptor.
Research Pipeline
| Program |
Devlopment Stage |
Indication |
| M1 PAM* |
Lead Optimization |
Gastrointestinal Disorders |
| P2X7 Antagonist |
Lead Optimization |
Pain and Inflammation |
| 5-HT1A Agonist |
Lead Optimization |
Treatment Resistant Depression |
| M4 PAM |
Hit to Lead |
Psychosis |
| Multimodal |
Hit Optimisation |
Bipolar Disorders |